Tranilast
Angiogenesis inhibitor
Product Specifications
Background
Tranilast is an antiallergic, antifibrotic drug that inhibits collagen synthesis, when administered in a dose –dependent manner for a 48 h treatment (1). As an antifibrotic agent, studies shown an effect on the growth of metastasis of mammary carcinoma. It is associated with the inhibition of the growth factor –beta. (TGF-beta) (2).
CAS Number
53902-12-8
Product Name Alternative
2-{[ (2E) -3- (3,4-dimethoxyphenyl) prop-2- enoyl]amino}benzoic acid
UNSPSC
41116105
Type
Inhibitor
Source
Synthetic
Field of Research
Cell Signaling | Neuroscience | Cancer | Cardiovascular System
Purity
≥95% (HPLC)
Weight
0.01
Format
Off-white to yellow powder.
Solubility
Soluble in DMSO.
Molecular Formula
C18H17NO5
Molecular Weight
327.33
Precautions
Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
References & Citations
1. Yamada H., Tajima S., Nishikawa T., Murad S., and Pinnell S., (1999) The Journal of Biochemistrystry. 116(4): 892-897.
2. Chakrabarti R., Subramanian V., Abadalla J., Jothy S., Predhomme GJ. (2009) Anticancer Drugs. 20(5): 334-45.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog